Alkemi Growth Capital Research
Investment Thesis
Alkemi Growth Capital is an India-focused healthcare and wellness growth fund. Its stated mission is to elevate the health and well-being of the Indian consumer while maximizing shareholder returns, framing well-being as a fourth basic need alongside food, clothing, and shelter. Alkemi invests exclusively in scalable companies with validated product-market fit, governance-aligned leadership, and a clear pathway to institutional scale. The firm describes its approach as combining sector specialization, high-conviction portfolio construction, and long-term partnership capital designed to accelerate market-leading companies with transformative potential in India's healthcare and wellness ecosystem.
Stage Focus
Alkemi's own branding leans growth capital, but its actual portfolio activity spans Seed through Series B: a Pre-Series A lead in Alphadroid ($3.8M / Rs 36 Cr, May 2026), a Rs 18 Cr growth round lead in MedVital (May 2026), participation in Chosen's $5M Series A (May 2026), participation in ZeroHarm Sciences' Rs 65 Cr Series A (Feb 2026), and continued participation in QuickClean's $14M Series B (Jul 2026). The firm is comfortable investing from early growth through later, more capital-intensive rounds within its healthcare/wellness mandate.
Check Size
No explicit check-size range is published on the website. Observed round participation ranges from roughly $1.4M (earlier Jobizo pre-Series A) up to co-investing in $14M+ Series B rounds (QuickClean), suggesting a working check size in the low single-digit millions of dollars per investment, sized up for follow-ons in winners.
Lead Tendency
Mixed. Alkemi is credited as lead investor in several rounds (Alphadroid's Pre-Series A, MedVital's Rs 18 Cr round), but appears as a participating/co-investor in others led by different firms (Chosen's Series A led by Fireside Ventures; ZeroHarm Sciences' Series A led by Kotak Life Sciences Fund; QuickClean's Series B led by Stakeboat Capital).
Recent Activity
Alkemi has been active through 2026: leading a $3.8M Pre-Series A in robotics startup Alphadroid (May 2026), leading a Rs 18 Cr round in wound-care/regenerative-aesthetics startup MedVital (May 2026), participating in dermocosmetics brand Chosen's $5M Series A alongside Fireside Ventures and L'Oreal's BOLD (May 2026), co-investing in nutraceutical brand ZeroHarm Sciences' Rs 65 Cr Series A alongside Kotak Life Sciences Fund (Feb 2026), and continuing to back on-premise laundry infrastructure company QuickClean through its $14M Series B led by Stakeboat Capital (Jul 2026).
Portfolio Highlights
The portfolio spans 19+ companies within Indian healthcare, wellness, and adjacent consumer categories: Redcliffe Labs (diagnostics), Pee Safe (hygiene products), Uncover (skincare/dermatology), Docquity (verified doctor network), MedKart (generic-medicine pharmacy chain), Doceree (physician-engagement/health marketing network), Farmley and Slurrp Farm (healthy food brands), Saveo (pharma B2B distribution), Medulance (emergency medical transport tech), Datar Cancer Genetics (liquid biopsy / molecular diagnostics), Jobizo (healthcare blue-collar HRtech), Jagruti Rehab (addiction rehabilitation), Doxper (clinical documentation), QuickClean (laundry infrastructure for institutional/hospital settings), Alphadroid (robotics), MedVital (wound care), Chosen (dermocosmetics), and ZeroHarm Sciences (nano-formulated nutraceuticals).
Team
- Alka Goel, Founder & Managing Partner - Launched Alkemi in 2017 after relocating from New York to Delhi to invest in Indian healthcare startups; frequently cited in press (VCCircle, Venture Capital Journal, Private Equity International) as the firm's founding investor and public face.
- Dr. Mansi Aggarwal, Partner - Co-leads investment activity and founder engagement alongside Goel; interviewed in Express Healthcare's September 2026 issue and regularly appears in portfolio-company funding announcements.
- Jagannath Banavalikar, Investment Team
- Rony Saha, Investment Team
- Vedant Anand, Investment Team
- Advisory board: Shantanu Mukerji (Managing Director, Gulf Capital), Utsav Baijal (Head, India Private Equity, Bain Capital), Priyanka Aggarwal (Managing Director & Partner, BCG), Rohit Kapoor (CEO, Swiggy Food Marketplace), Pankaj Sahni (Group CEO, Medanta/Global Health Limited), Abhishek Kalra (Former MD, Lehman Brothers), and Vikas Bhadoria (Former Senior Partner, McKinsey & Company).
Decision Process
A small, partnership-led investment team supported by a deep bench of sector advisors from healthcare, private equity, and consulting backgrounds - consistent with a partnership-style decision process rather than a solo-GP or large investment-committee structure.
Founder Preferences
Alkemi's site explicitly seeks bold and determined founders building disruptive, high-performing companies, describing its ideal partners as entrepreneurs inspired by a vision, with boldness in their DNA, who persevere under uncertainty. The firm emphasizes governance-aligned leadership and validated product-market fit as pre-conditions for investment, and positions itself as a hands-on partner post-investment (process institutionalization, revenue-expansion support via its operator/clinical network, capital discipline, follow-on facilitation).
Geographic Focus
Exclusively India-focused, headquartered in New Delhi, targeting the Indian healthcare and wellness consumer market.
Fund Structure
Alkemi manages at least two SEBI-registered Category II AIFs: Alkemi Venture Fund I (SEBI Reg. No. IN/AIF2/18-19/0533) and Alkemi Venture Fund II - Scheme I (SEBI Reg. No. IN/AIF2/21-22/0984), both managed by Alkemi Growth Capital LLP. External sources indicate Fund II targeted a $75M raise with a first close of approximately $49.7M.